Acetylsalicylic acid and the balance between prostacyclin and thromboxane A2

References

• Samuelsson B. An elucidation of arachidonic acid cascade. Discovery of prostaglandins, thromboxane and leukotrienes. Drugs 1987; 33(Suppl 1)2–9
   PubMed Web of Science ®Google Scholar
• Vane J. R., Bunting S., Moncada S. Prostacyclin in physiology and pathophysiology. Int Rev Exp Path 1982; 23: 161–207
   PubMedGoogle Scholar
• Ross R. The pathogenesis of atherosclerosis—an update. N Engl J Med 1986; 314: 488–500
   PubMed Web of Science ®Google Scholar
• Ylikorkala O., Mäkilä U-M. Prostacyclin and thromboxane in gynecology and obstetrics. Am J Obstet Gynecol 1985; 152: 318–29
   PubMed Web of Science ®Google Scholar
• Mäkilä U-M, Jouppila P., Kirkinen P., Viinikka L., Ylikorkala O. Relation between umbilical prostacy-clin production and blood-flow in the fetus. Lancet 1983; 1: 728–9
   PubMed Web of Science ®Google Scholar
• Vane J. R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol 1971; 231: 232–5
   PubMedGoogle Scholar
• Smith J. B., Willis A. L. Aspirin selectively inhibits prostaglandin production in human platelets. Nature New Biol 1971; 231: 235–7
   PubMedGoogle Scholar
• Roth G. J., Stanford N., Majerus P. Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci USA 1975; 72: 3073–6
   PubMed Web of Science ®Google Scholar
• Roth G. J., Majerus P. W. The mechanism of the effect of aspirin on human platelets. 1. Acetylation of a paniculate fraction protein. J Clin Invest 1975; 56: 624–32
   PubMed Web of Science ®Google Scholar
• Pedersen A. K., Fitz Gerald G. A. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med 1984; 311: 1206–11
   PubMed Web of Science ®Google Scholar
• Merino J., Livio M., Rajtar G., de Gaetano G. Salicylate reverses in vitro aspirin inihibition of rat platelet and vascular prostaglandin generation. Biochem Pharmacol 1980; 29: 1093–6
   PubMed Web of Science ®Google Scholar
• Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet therapy. Br Med J 1988; 296: 320–31
   PubMed Web of Science ®Google Scholar
• Steering Committee of the Physicians Health Study Research Group. Final report on the aspirin component of the ongoing physicians' health study. N Engl J Med 1989; 321: 129–35
   PubMed Web of Science ®Google Scholar
• Peto R., Gray R., Collins R., et al. Randomized trial of prophylactic daily aspirin in British male doctors. Br Med J 1988; 296: 313–6
   PubMed Web of Science ®Google Scholar
• Wallenburg H. CS, Dekker G. A., Makovitz J. W., Rotmans P. Low-dose aspirin prevents pregnancy-induced hypertension and pre-eclampsia in angiotensin-sensitive primigravidae. Lancet 1986; 1: 1–3
   PubMed Web of Science ®Google Scholar
• Wallenburg H. CS, Rotmans N. Prevention of recurrent idiopathic fetal growth retardation by low-dose aspirin and dipyridamole. Am J Obstet Gynecol 1987; 157: 1230–5
   PubMed Web of Science ®Google Scholar
• Schiff E., Peleg E., Goldenberg M., et al. The use of aspirin to prevent pregnancy-induced hypertension and lower the ratio of thromboxane A2 to prostacyclin in relatively high risk pregnancies. N Engl J Med 1989; 321: 351–6
   PubMed Web of Science ®Google Scholar
• Benigni A., Gregorini G., Frusca T., et al. Effect of low-dose aspirin on fetal and maternal generation of thromboxane by platelets in women at risk for pregnancy-induced hypertension. N Engl J Med 1989; 321: 357–62
   PubMed Web of Science ®Google Scholar
• Preston E. F., Whipps S., Jackson C. A., French A. J., Wyld P. J., Stoddard C. J. Inhibition of prostacyclin and platelet thromboxane A2 after low-dose aspirin. N Engl J Med 1981; 304: 76–9
   PubMed Web of Science ®Google Scholar
• Weksler B., Pett S., Alono D., et al. Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients. N Engl J Med 1983; 308: 800–5
   PubMed Web of Science ®Google Scholar
• Viinikka L., Ylikorkala O. Measurement of thromboxane B2 in human plasma and serum by radio-immunoassay. Prostaglandins 1980; 20: 759–66
   PubMed Web of Science ®Google Scholar
• Patrono C., Ciabattoni G., Pinca E., et al. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res 1980; 17: 317–27
   PubMed Web of Science ®Google Scholar
• Hanley S. P., Bevan J., Cockbill S. R., Heptinstall S. Differential inhibition by low-dose aspirin of human venous prostacyclin synthesis and platelet thromboxane synthesis. Lancet 1981; 1: 969–71
   PubMed Web of Science ®Google Scholar
• Fitz Gerald G. A., Pedersen A. K., Patrono C. Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. Circulation 1983; 67: 1174–7
   PubMed Web of Science ®Google Scholar
• Patrignani P., Filabozzi P., Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982; 70: 1366–72
   Web of Science ®Google Scholar
• FitzGerald G. A., Oates J. A., Hawiger J., Maas R. L., Roberts L. J., Lawson J. A., Brash A. R. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest 1983; 71: 678–88
   Web of Science ®Google Scholar
• Vesterqvist O. Measurements of the in vivo synthesis of thromboxane and prostacyclin in humans. Scand J Clin Invest 1988; 48: 401–7
   PubMed Web of Science ®Google Scholar
• Ylikorkala O., Kuusi T., Tikkanen I., Viinikka L. Desogestrel-and levonorgestrel-containing oral contraceptives have different effects on urinary excretion of prostacyclin metabolites and serum high density lipoproteins. J Clin Endocrinol Metab 1987; 65: 1238–42
   PubMed Web of Science ®Google Scholar
• Viinikka L., Ylikorkala O. Effect of various doses of acetylsalicylic acid in combination with dipyridamole on the balance between prostacyclin and thromboxane in human serum. Br J Pharmacol 1981; 72: 299–303
   PubMed Web of Science ®Google Scholar
• FitzGerald G. A., Oates J. A. Selective and nonselective inhibition of thromboxane formation. Clin Pharmacol Ther 1984; 35: 633–40
   PubMed Web of Science ®Google Scholar
• Viinikka L., Salokannel J., Ylikorkala O. Effect of prolonged treatment with acetylsalicylic acid and dipyridamole on platelet thromboxane A2 production in atherosclerotic subjects. Prostaglandins Leukotrienes and Medicine 1983; 11: 45–50
   PubMedGoogle Scholar
• Toivanen J., Ylikorkala O., Viinikka L. One milligramme of acetylsalicylic acid daily inhibits platelet thromboxane A2 production. Thromb Res 1984; 35: 681–7
   PubMed Web of Science ®Google Scholar
• Rasmanis G., Vesterqvist O., Green K., Edhag O. Effects of intermittent treatment with aspirin on thromboxane and prostacyclin formation in patients with myocardial infarction. Lancet 1988; 2: 245–7
   PubMed Web of Science ®Google Scholar
• O'Brien J. R. Effects of salicylates on human platelets. Lancet 1968; 1: 779–83
   PubMed Web of Science ®Google Scholar
• Cerskus A. L., Ali M., Davies B. J., McDonald J. WD. Possible significance of small numbers of functional platelets in a population of aspirin-treated platelets in vitro. Thromb Res 1980; 18: 389–97
   PubMed Web of Science ®Google Scholar
• Di Minno G., Silver M. J., Murphy S. Monitoring the entry of new platelets into the circulation after ingestion of aspirin. Blood 1983; 61: 1081–5
   PubMed Web of Science ®Google Scholar